%20(1).avif)
.avif)
Metabolic Health Starts in the
Portal-Hepatic Region
The Portal-Hepatic Region is the body’s metabolic control center, integrating signals from insulin, GLP-1, and serotonin as they travel the portal-hepatic circulation. Together, these hormones regulate glucose and fat metabolism, nutrient storage, and appetite—linking the gut, liver, and brain in the physiologic control of energy balance.
Why Hepatocytes Matter
Hepatocytes are the liver’s functional core—utilizing and clearing insulin, GLP-1, and serotonin as they enter the liver through the portal vein. These specialized cells regulate how the body stores nutrients and controls whole-body blood glucose and fat metabolism. Today’s therapies struggle to reach hepatocytes and instead act in peripheral tissues. This divergence from natural physiology contributes to diminished efficacy, greater side effects, and limited durability.
Hepatocyte Directed Vesicle (HDV™) Platform
HDV™ enables access to this mechanism-rich environment, shifting drug action from peripheral tissues to where metabolism begins.
Advancing Next-Generation Therapies
HDV™ is a first-in-class platform that delivers drug actives to the portal-hepatic region with precision. HDV is safe and compatible with a wide range of active pharmaceutical ingredients. HDV offers a scalable and differentiated approach to developing the next generation of metabolic therapies.
Advancing breakthrough therapies
Diasome’s research pipeline is focused on advancing therapies across three key areas:
.avif)
.avif)
.avif)
A portfolio focused on the unmet needs in
diabetes, obesity, and fatty liver disease.
Committed to Breakthroughs. Focused on Outcomes.
Diasome is led by world-renowned researchers, clinicians, and biotech experts dedicated to advancing metabolic therapies.
Since our founding, we have worked tirelessly to bridge the gap between scientific discovery and real-world patient impact.
.avif)
.jpg)
.jpg)